Andrea Sarah Foulkes, Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Genetic | 9 | 2011 | 3602 | 1.270 |
Why?
|
| Models, Statistical | 11 | 2019 | 5104 | 1.220 |
Why?
|
| Metabolic Diseases | 2 | 2020 | 632 | 0.920 |
Why?
|
| Likelihood Functions | 4 | 2018 | 1013 | 0.920 |
Why?
|
| Software Validation | 1 | 2021 | 62 | 0.890 |
Why?
|
| Synteny | 1 | 2020 | 83 | 0.880 |
Why?
|
| Genome-Wide Association Study | 11 | 2020 | 11019 | 0.850 |
Why?
|
| Multifactorial Inheritance | 3 | 2020 | 969 | 0.810 |
Why?
|
| Polymorphism, Single Nucleotide | 17 | 2020 | 15296 | 0.760 |
Why?
|
| HIV-1 | 22 | 2015 | 6711 | 0.680 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 525 | 0.640 |
Why?
|
| Genetic Loci | 3 | 2016 | 2575 | 0.630 |
Why?
|
| Gene Expression Profiling | 5 | 2020 | 9661 | 0.610 |
Why?
|
| HIV Infections | 30 | 2019 | 14979 | 0.540 |
Why?
|
| Anti-HIV Agents | 15 | 2015 | 3955 | 0.510 |
Why?
|
| Haplotypes | 5 | 2008 | 2913 | 0.500 |
Why?
|
| Bayes Theorem | 4 | 2020 | 1848 | 0.500 |
Why?
|
| Genotype | 14 | 2011 | 13073 | 0.470 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2012 | 1917 | 0.450 |
Why?
|
| Algorithms | 7 | 2021 | 13500 | 0.450 |
Why?
|
| Blood Sedimentation | 2 | 2022 | 238 | 0.420 |
Why?
|
| Dyslipidemias | 6 | 2022 | 815 | 0.410 |
Why?
|
| Biostatistics | 1 | 2011 | 162 | 0.380 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2022 | 447 | 0.370 |
Why?
|
| Indinavir | 3 | 2003 | 74 | 0.360 |
Why?
|
| Research Design | 2 | 2021 | 5835 | 0.350 |
Why?
|
| Lipase | 5 | 2008 | 312 | 0.340 |
Why?
|
| Atrial Fibrillation | 2 | 2021 | 4038 | 0.340 |
Why?
|
| Obesity | 5 | 2022 | 11700 | 0.340 |
Why?
|
| Genomics | 3 | 2020 | 4921 | 0.330 |
Why?
|
| Observation | 1 | 2008 | 319 | 0.310 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2019 | 4355 | 0.310 |
Why?
|
| Genetic Association Studies | 2 | 2018 | 2722 | 0.300 |
Why?
|
| Cardiovascular Diseases | 7 | 2020 | 13413 | 0.290 |
Why?
|
| Disease | 1 | 2011 | 714 | 0.290 |
Why?
|
| Data Interpretation, Statistical | 3 | 2007 | 2760 | 0.280 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 13444 | 0.280 |
Why?
|
| Apolipoprotein C-III | 1 | 2006 | 198 | 0.280 |
Why?
|
| Cervix Uteri | 3 | 2019 | 564 | 0.280 |
Why?
|
| Computational Biology | 2 | 2015 | 3612 | 0.280 |
Why?
|
| Virus Integration | 4 | 2015 | 303 | 0.270 |
Why?
|
| HIV Protease Inhibitors | 3 | 2006 | 432 | 0.270 |
Why?
|
| Interferon-alpha | 3 | 2013 | 925 | 0.270 |
Why?
|
| Mucous Membrane | 2 | 2019 | 680 | 0.260 |
Why?
|
| Regression Analysis | 2 | 2011 | 6669 | 0.260 |
Why?
|
| Macrophage Activation | 2 | 2017 | 589 | 0.260 |
Why?
|
| Endotoxemia | 2 | 2017 | 225 | 0.250 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 2228 | 0.250 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 1730 | 0.250 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2019 | 590 | 0.240 |
Why?
|
| Consciousness Disorders | 2 | 2021 | 215 | 0.230 |
Why?
|
| Computer Simulation | 6 | 2017 | 6120 | 0.230 |
Why?
|
| Humans | 72 | 2022 | 686663 | 0.230 |
Why?
|
| Myocardium | 1 | 2016 | 5024 | 0.230 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2014 | 2578 | 0.230 |
Why?
|
| Gene Dosage | 1 | 2007 | 1281 | 0.230 |
Why?
|
| Lipids | 2 | 2013 | 3131 | 0.230 |
Why?
|
| Vagina | 2 | 2019 | 761 | 0.230 |
Why?
|
| Simian immunodeficiency virus | 2 | 2019 | 865 | 0.220 |
Why?
|
| Photoplethysmography | 1 | 2021 | 51 | 0.220 |
Why?
|
| Coma, Post-Head Injury | 1 | 2020 | 20 | 0.220 |
Why?
|
| Databases, Genetic | 2 | 2020 | 1818 | 0.210 |
Why?
|
| Virus Replication | 5 | 2015 | 2589 | 0.210 |
Why?
|
| Triglycerides | 2 | 2006 | 2493 | 0.210 |
Why?
|
| Heredity | 1 | 2020 | 164 | 0.210 |
Why?
|
| Viral Load | 8 | 2015 | 3216 | 0.200 |
Why?
|
| Semen | 2 | 2019 | 237 | 0.200 |
Why?
|
| Phenotype | 8 | 2019 | 16091 | 0.200 |
Why?
|
| Inflammation | 4 | 2021 | 9617 | 0.190 |
Why?
|
| Leukocyte Count | 2 | 2022 | 1700 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2020 | 17071 | 0.190 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 213 | 0.190 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 3569 | 0.190 |
Why?
|
| Ferritins | 1 | 2022 | 555 | 0.190 |
Why?
|
| Hospital Mortality | 3 | 2022 | 5065 | 0.180 |
Why?
|
| Sampling Studies | 1 | 2020 | 653 | 0.180 |
Why?
|
| Selection Bias | 1 | 2020 | 348 | 0.180 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2021 | 592 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2008 | 1424 | 0.170 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 1195 | 0.160 |
Why?
|
| Hospitals, General | 1 | 2020 | 699 | 0.160 |
Why?
|
| Niacin | 1 | 2017 | 113 | 0.160 |
Why?
|
| Confidentiality | 1 | 2021 | 602 | 0.160 |
Why?
|
| Chemokine CX3CL1 | 1 | 2015 | 51 | 0.150 |
Why?
|
| Female | 41 | 2022 | 375459 | 0.150 |
Why?
|
| Middle Aged | 28 | 2022 | 216468 | 0.150 |
Why?
|
| Aged | 20 | 2022 | 162271 | 0.150 |
Why?
|
| Linkage Disequilibrium | 2 | 2017 | 2049 | 0.140 |
Why?
|
| Dendritic Cells | 4 | 2015 | 2779 | 0.140 |
Why?
|
| Glutathione Transferase | 2 | 2007 | 623 | 0.140 |
Why?
|
| Probability | 1 | 2020 | 2508 | 0.140 |
Why?
|
| Male | 33 | 2022 | 352465 | 0.140 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2007 | 449 | 0.130 |
Why?
|
| Disease Susceptibility | 3 | 2016 | 1812 | 0.130 |
Why?
|
| Biometry | 1 | 2017 | 535 | 0.130 |
Why?
|
| Myocardial Infarction | 4 | 2016 | 11266 | 0.130 |
Why?
|
| Open Reading Frames | 1 | 2017 | 855 | 0.130 |
Why?
|
| Adult | 30 | 2022 | 211400 | 0.130 |
Why?
|
| Language | 1 | 2021 | 1121 | 0.130 |
Why?
|
| Linear Models | 3 | 2017 | 6088 | 0.130 |
Why?
|
| Intensive Care Units | 3 | 2022 | 3263 | 0.130 |
Why?
|
| DNA, Viral | 2 | 2012 | 2341 | 0.120 |
Why?
|
| Viremia | 5 | 2012 | 684 | 0.120 |
Why?
|
| Interferons | 1 | 2015 | 610 | 0.120 |
Why?
|
| Pedigree | 1 | 2020 | 4792 | 0.120 |
Why?
|
| Cross-Sectional Studies | 8 | 2020 | 21640 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2022 | 3105 | 0.120 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2011 | 63 | 0.110 |
Why?
|
| Bacterial Translocation | 1 | 2011 | 81 | 0.110 |
Why?
|
| Macrophages | 2 | 2017 | 5748 | 0.110 |
Why?
|
| Body Composition | 1 | 2021 | 2381 | 0.110 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 468 | 0.110 |
Why?
|
| Endometrium | 1 | 2014 | 400 | 0.110 |
Why?
|
| Cholesterol, HDL | 2 | 2008 | 1768 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2016 | 1137 | 0.100 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 1363 | 0.100 |
Why?
|
| Protein Precursors | 1 | 2015 | 1198 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2008 | 3713 | 0.100 |
Why?
|
| Antiviral Agents | 2 | 2013 | 2625 | 0.100 |
Why?
|
| Prospective Studies | 9 | 2021 | 49071 | 0.100 |
Why?
|
| Inpatients | 1 | 2020 | 2050 | 0.100 |
Why?
|
| Resource Allocation | 1 | 2012 | 356 | 0.100 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 588 | 0.100 |
Why?
|
| African Americans | 2 | 2020 | 5144 | 0.100 |
Why?
|
| Cluster Analysis | 4 | 2009 | 2776 | 0.100 |
Why?
|
| Brain Injuries | 1 | 2020 | 1819 | 0.090 |
Why?
|
| Ketamine | 1 | 2013 | 408 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 3 | 2009 | 1513 | 0.090 |
Why?
|
| Statistical Distributions | 1 | 2008 | 64 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 5114 | 0.090 |
Why?
|
| AIDS Serodiagnosis | 1 | 2009 | 184 | 0.090 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2008 | 120 | 0.090 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 554 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 16227 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2021 | 6435 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 10088 | 0.090 |
Why?
|
| Lipopolysaccharides | 2 | 2016 | 2249 | 0.090 |
Why?
|
| Brucella abortus | 1 | 2006 | 12 | 0.090 |
Why?
|
| Antigens, Viral | 1 | 2012 | 1146 | 0.090 |
Why?
|
| Autoantigens | 1 | 2012 | 914 | 0.090 |
Why?
|
| RNA | 1 | 2017 | 2493 | 0.090 |
Why?
|
| Cohort Studies | 10 | 2022 | 38732 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 268 | 0.080 |
Why?
|
| Brucellosis | 1 | 2006 | 18 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 2842 | 0.080 |
Why?
|
| Thyrotoxicosis | 1 | 2007 | 81 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3016 | 0.080 |
Why?
|
| Benzoxazines | 1 | 2008 | 304 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 833 | 0.080 |
Why?
|
| Consciousness | 2 | 2020 | 358 | 0.080 |
Why?
|
| Risk Factors | 8 | 2022 | 69278 | 0.080 |
Why?
|
| Killer Cells, Natural | 3 | 2011 | 2191 | 0.080 |
Why?
|
| South Africa | 4 | 2011 | 1496 | 0.080 |
Why?
|
| Immunity, Innate | 3 | 2007 | 2892 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2022 | 59331 | 0.080 |
Why?
|
| Sex Factors | 1 | 2021 | 10926 | 0.080 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2016 | 1532 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2022 | 60991 | 0.080 |
Why?
|
| Health Resources | 1 | 2012 | 931 | 0.070 |
Why?
|
| Telemedicine | 1 | 2021 | 2270 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 4115 | 0.070 |
Why?
|
| Plasmodium | 1 | 2007 | 223 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 1995 | 0.070 |
Why?
|
| Apolipoprotein A-I | 1 | 2006 | 274 | 0.070 |
Why?
|
| Bacteremia | 1 | 2011 | 945 | 0.070 |
Why?
|
| Apolipoproteins | 1 | 2007 | 293 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2020 | 3836 | 0.070 |
Why?
|
| Interleukin-12 | 1 | 2006 | 601 | 0.070 |
Why?
|
| Nelfinavir | 1 | 2003 | 77 | 0.070 |
Why?
|
| Recovery of Function | 2 | 2021 | 2965 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 2157 | 0.070 |
Why?
|
| Receptors, CCR5 | 2 | 2019 | 449 | 0.060 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 1572 | 0.060 |
Why?
|
| Aging | 1 | 2022 | 8222 | 0.060 |
Why?
|
| HIV | 2 | 2011 | 1444 | 0.060 |
Why?
|
| Genome, Human | 1 | 2016 | 4458 | 0.060 |
Why?
|
| Stavudine | 2 | 2012 | 95 | 0.060 |
Why?
|
| Asthma | 1 | 2020 | 5725 | 0.060 |
Why?
|
| Leptin | 1 | 2010 | 1604 | 0.060 |
Why?
|
| Adiposity | 1 | 2011 | 1656 | 0.060 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 675 | 0.060 |
Why?
|
| Lymphocyte Activation | 5 | 2015 | 5989 | 0.060 |
Why?
|
| Hospitalization | 4 | 2022 | 9304 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2020 | 23739 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 459 | 0.060 |
Why?
|
| Software | 1 | 2015 | 4314 | 0.050 |
Why?
|
| Saquinavir | 1 | 2000 | 30 | 0.050 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2011 | 1782 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2013 | 3101 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2006 | 19328 | 0.050 |
Why?
|
| Ritonavir | 2 | 2012 | 279 | 0.050 |
Why?
|
| Young Adult | 4 | 2021 | 56052 | 0.050 |
Why?
|
| Intubation | 1 | 2020 | 142 | 0.050 |
Why?
|
| Spleen | 1 | 2006 | 2570 | 0.050 |
Why?
|
| Macaca mulatta | 2 | 2019 | 2418 | 0.050 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 136 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 13204 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2011 | 1665 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 14656 | 0.050 |
Why?
|
| Headache | 1 | 2007 | 1063 | 0.050 |
Why?
|
| Monocytes | 1 | 2009 | 2643 | 0.050 |
Why?
|
| Malaria | 1 | 2007 | 1037 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 10329 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 12680 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 4958 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2016 | 11833 | 0.040 |
Why?
|
| Multigene Family | 1 | 2002 | 1200 | 0.040 |
Why?
|
| Massachusetts | 2 | 2021 | 8920 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2020 | 10108 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2006 | 2823 | 0.040 |
Why?
|
| Boston | 2 | 2020 | 9534 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2002 | 805 | 0.040 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2015 | 25 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 5182 | 0.040 |
Why?
|
| Pakistan | 1 | 2016 | 296 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2017 | 20620 | 0.040 |
Why?
|
| Perforin | 1 | 2015 | 174 | 0.040 |
Why?
|
| Waist-Hip Ratio | 1 | 2016 | 530 | 0.030 |
Why?
|
| Arousal | 1 | 2020 | 1122 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2020 | 2697 | 0.030 |
Why?
|
| United States | 1 | 2022 | 65579 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 4436 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 4129 | 0.030 |
Why?
|
| HIV Protease | 2 | 2005 | 98 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2020 | 11866 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2015 | 485 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1100 | 0.030 |
Why?
|
| Prognosis | 4 | 2019 | 28923 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 5223 | 0.030 |
Why?
|
| Interferon-gamma | 2 | 2015 | 3263 | 0.030 |
Why?
|
| Disease Reservoirs | 1 | 2012 | 144 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2015 | 507 | 0.030 |
Why?
|
| Logistic Models | 2 | 2020 | 13807 | 0.030 |
Why?
|
| Midazolam | 1 | 2013 | 243 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 1551 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2016 | 660 | 0.030 |
Why?
|
| Cytokines | 2 | 2019 | 7147 | 0.030 |
Why?
|
| Plasma | 1 | 2014 | 558 | 0.030 |
Why?
|
| Time Factors | 5 | 2015 | 42271 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2021 | 67320 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2011 | 6230 | 0.030 |
Why?
|
| Lamivudine | 1 | 2011 | 331 | 0.030 |
Why?
|
| Serum | 1 | 2011 | 224 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2012 | 648 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 19153 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2384 | 0.020 |
Why?
|
| Zidovudine | 1 | 2011 | 621 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2005 | 15407 | 0.020 |
Why?
|
| Self Report | 1 | 2020 | 3341 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 241 | 0.020 |
Why?
|
| Adipocytes | 1 | 2016 | 1204 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2021 | 3232 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2021 | 7791 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2013 | 699 | 0.020 |
Why?
|
| Carbimazole | 1 | 2007 | 4 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2007 | 3061 | 0.020 |
Why?
|
| Alkynes | 1 | 2008 | 326 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 1930 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2009 | 516 | 0.020 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2006 | 33 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 33186 | 0.020 |
Why?
|
| Antithyroid Agents | 1 | 2007 | 73 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 12734 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2008 | 431 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1721 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 6329 | 0.020 |
Why?
|
| Mutation | 4 | 2007 | 28848 | 0.020 |
Why?
|
| Malaria Vaccines | 1 | 2007 | 143 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 3103 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2007 | 664 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 807 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 673 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2015 | 2355 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2015 | 1847 | 0.020 |
Why?
|
| Graves Disease | 1 | 2007 | 248 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2021 | 6421 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2005 | 6030 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 1516 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10648 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 1604 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2005 | 112 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2007 | 7195 | 0.020 |
Why?
|
| Triage | 1 | 2012 | 932 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 3557 | 0.020 |
Why?
|
| Brain | 2 | 2021 | 24202 | 0.020 |
Why?
|
| Registries | 1 | 2021 | 8033 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 7140 | 0.020 |
Why?
|
| Smoking | 1 | 2021 | 9029 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2007 | 591 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 1446 | 0.020 |
Why?
|
| Mortality | 1 | 2015 | 2822 | 0.020 |
Why?
|
| Pandemics | 1 | 2022 | 5859 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2020 | 12323 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 6464 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 19308 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6970 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 7060 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 2207 | 0.010 |
Why?
|
| Markov Chains | 1 | 2005 | 992 | 0.010 |
Why?
|
| Animals | 4 | 2019 | 170849 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 1734 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2005 | 907 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 2005 | 907 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 18495 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12525 | 0.010 |
Why?
|
| Monte Carlo Method | 1 | 2005 | 1301 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2016 | 24351 | 0.010 |
Why?
|
| Mothers | 1 | 2009 | 1978 | 0.010 |
Why?
|
| Glucose | 1 | 2010 | 4016 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 2912 | 0.010 |
Why?
|
| Heterozygote | 1 | 2005 | 2787 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 1914 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 39737 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20409 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 880 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2012 | 3793 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6786 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 4477 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 8070 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4415 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6685 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 10102 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 13729 | 0.010 |
Why?
|
| Apoptosis | 1 | 2009 | 10261 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10766 | 0.010 |
Why?
|
| Child | 2 | 2009 | 71361 | 0.010 |
Why?
|
| Infant | 1 | 2011 | 33918 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 8882 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 8610 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 23439 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 11115 | 0.000 |
Why?
|
| Adolescent | 1 | 2009 | 84957 | 0.000 |
Why?
|
| Mice | 1 | 2006 | 80803 | 0.000 |
Why?
|